铅（Pb）的情况真的会发生吗？继镥（Lu）/锕（Ac）之后的重磅事件？ - Suppr

Suppr

超能文献

Is Pb Really Happening? The Post-Lu/Ac Blockbuster?

作者信息

Zimmermann Richard

机构信息

Chrysalium Consulting, Lalaye, France;

MEDraysintell, Louvain-la-Neuve, Belgium; and.

出版信息

J Nucl Med. 2024 Feb 1;65(2):176-177. doi: 10.2967/jnumed.123.266774.

DOI:10.2967/jnumed.123.266774

PMID:38176723

Abstract

摘要

相似文献

Is Pb Really Happening? The Post-Lu/Ac Blockbuster?

J Nucl Med. 2024 Feb 1;65(2):176-177. doi: 10.2967/jnumed.123.266774.

Biodistribution and dosimetry for combined [Lu]Lu-PSMA-I&T/[Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging.

Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1280-1290. doi: 10.1007/s00259-022-06092-1. Epub 2023 Jan 11.

First preclinical evaluation of [Ac]Ac-DOTA-JR11 and comparison with [Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.

EJNMMI Radiopharm Chem. 2023 Jun 30;8(1):13. doi: 10.1186/s41181-023-00197-0.

Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome Study.

J Nucl Med. 2022 Jul 21. doi: 10.2967/jnumed.122.264043.

Fibroblast activation protein targeted therapy using [Lu]FAPI-46 compared with [Ac]FAPI-46 in a pancreatic cancer model.

Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):871-880. doi: 10.1007/s00259-021-05554-2. Epub 2021 Sep 18.

Therapeutic evaluation of [Pb]Pb-AB001 and [Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.

Eur J Nucl Med Mol Imaging. 2025 May 21. doi: 10.1007/s00259-025-07330-y.

Relative Efficacy of Ac-PSMA-617 and Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry.

Mol Imaging Radionucl Ther. 2022 Feb 2;31(1):1-6. doi: 10.4274/mirt.galenos.2021.63308.

Ac-PSMA-617/Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.

Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):721-728. doi: 10.1007/s00259-019-04612-0. Epub 2019 Nov 22.

Efficacy and Safety of [Ac]Ac-PSMA-617 Augmented [Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.

Pharmaceutics. 2021 May 14;13(5):722. doi: 10.3390/pharmaceutics13050722.

Tandem Isotope Therapy with Ac- and Lu-PSMA-617 in a Murine Model of Prostate Cancer.

J Nucl Med. 2023 Nov;64(11):1772-1778. doi: 10.2967/jnumed.123.265433. Epub 2023 Oct 5.

引用本文的文献

Cytotoxicity of Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models.

EJNMMI Radiopharm Chem. 2025 Aug 30;10(1):58. doi: 10.1186/s41181-025-00382-3.

Minimising the impact of stable Pb on recovery of Pb from a generator.

EJNMMI Radiopharm Chem. 2025 Jul 30;10(1):49. doi: 10.1186/s41181-025-00357-4.

Pb in targeted radionuclide therapy: a review.

EJNMMI Radiopharm Chem. 2025 Jul 1;10(1):34. doi: 10.1186/s41181-025-00362-7.

Therapeutic evaluation of [Pb]Pb-AB001 and [Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.

Eur J Nucl Med Mol Imaging. 2025 May 21. doi: 10.1007/s00259-025-07330-y.

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.

J Nucl Med. 2025 May 1;66(5):732-738. doi: 10.2967/jnumed.124.269299.

Long-Term Safety and Survival Outcomes of [Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [Ac]Ac-/[Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.

Cancers (Basel). 2025 Jan 26;17(3):405. doi: 10.3390/cancers17030405.

Aspects and prospects of preclinical theranostic radiopharmaceutical development.

Theranostics. 2024 Oct 7;14(17):6446-6470. doi: 10.7150/thno.100339. eCollection 2024.

Production and regulatory issues for theranostics.

Lancet Oncol. 2024 Jun;25(6):e260-e269. doi: 10.1016/S1470-2045(24)00041-X.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Is Pb Really Happening? The Post-Lu/Ac Blockbuster?

作者信息

Zimmermann Richard

机构信息

Chrysalium Consulting, Lalaye, France;

MEDraysintell, Louvain-la-Neuve, Belgium; and.

出版信息

J Nucl Med. 2024 Feb 1;65(2):176-177. doi: 10.2967/jnumed.123.266774.

DOI:10.2967/jnumed.123.266774

PMID:38176723

Abstract

摘要

相似文献

Is Pb Really Happening? The Post-Lu/Ac Blockbuster?

J Nucl Med. 2024 Feb 1;65(2):176-177. doi: 10.2967/jnumed.123.266774.

Biodistribution and dosimetry for combined [Lu]Lu-PSMA-I&T/[Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging.

Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1280-1290. doi: 10.1007/s00259-022-06092-1. Epub 2023 Jan 11.

First preclinical evaluation of [Ac]Ac-DOTA-JR11 and comparison with [Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.

EJNMMI Radiopharm Chem. 2023 Jun 30;8(1):13. doi: 10.1186/s41181-023-00197-0.

J Nucl Med. 2022 Jul 21. doi: 10.2967/jnumed.122.264043.

Fibroblast activation protein targeted therapy using [Lu]FAPI-46 compared with [Ac]FAPI-46 in a pancreatic cancer model.

Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):871-880. doi: 10.1007/s00259-021-05554-2. Epub 2021 Sep 18.

Therapeutic evaluation of [Pb]Pb-AB001 and [Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.

Eur J Nucl Med Mol Imaging. 2025 May 21. doi: 10.1007/s00259-025-07330-y.

Relative Efficacy of Ac-PSMA-617 and Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry.

Mol Imaging Radionucl Ther. 2022 Feb 2;31(1):1-6. doi: 10.4274/mirt.galenos.2021.63308.

Ac-PSMA-617/Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.

Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):721-728. doi: 10.1007/s00259-019-04612-0. Epub 2019 Nov 22.

Efficacy and Safety of [Ac]Ac-PSMA-617 Augmented [Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.

Pharmaceutics. 2021 May 14;13(5):722. doi: 10.3390/pharmaceutics13050722.

Tandem Isotope Therapy with Ac- and Lu-PSMA-617 in a Murine Model of Prostate Cancer.

J Nucl Med. 2023 Nov;64(11):1772-1778. doi: 10.2967/jnumed.123.265433. Epub 2023 Oct 5.

引用本文的文献

Cytotoxicity of Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models.

EJNMMI Radiopharm Chem. 2025 Aug 30;10(1):58. doi: 10.1186/s41181-025-00382-3.

Minimising the impact of stable Pb on recovery of Pb from a generator.

EJNMMI Radiopharm Chem. 2025 Jul 30;10(1):49. doi: 10.1186/s41181-025-00357-4.

Pb in targeted radionuclide therapy: a review.

EJNMMI Radiopharm Chem. 2025 Jul 1;10(1):34. doi: 10.1186/s41181-025-00362-7.

Therapeutic evaluation of [Pb]Pb-AB001 and [Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.

Eur J Nucl Med Mol Imaging. 2025 May 21. doi: 10.1007/s00259-025-07330-y.

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.

J Nucl Med. 2025 May 1;66(5):732-738. doi: 10.2967/jnumed.124.269299.

Cancers (Basel). 2025 Jan 26;17(3):405. doi: 10.3390/cancers17030405.

Aspects and prospects of preclinical theranostic radiopharmaceutical development.

Theranostics. 2024 Oct 7;14(17):6446-6470. doi: 10.7150/thno.100339. eCollection 2024.

Production and regulatory issues for theranostics.

Lancet Oncol. 2024 Jun;25(6):e260-e269. doi: 10.1016/S1470-2045(24)00041-X.